• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

What is the Risk of Hemorrhage and DIC following D&E for Fetal Death?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Kerns et al. (Obstetrics & Gynecology, 2019) assessed the association between fetal death and risk of hemorrhage and disseminated intravascular coagulation (DIC) following D&E procedures

METHODS:

  • Retrospective cohort study
  • Participant data
    • All D&E data from one academic center (2009 to 2013)
  • Study design
    • Maternal and fetal data abstracted including complications  
    • Compared risk of hemorrhage and DIC among women undergoing D&E with fetal death and those without
    • Unadjusted and adjusted analyses were performed for the outcomes of hemorrhage, DIC, and other complications
      • Unadjusted analyses only was performed for DIC as there were insufficient cases for adjustment of covariates

RESULTS:

  • 92 cases of D&E for fetal death | 4,428 cases of D&E for other indications

Hemorrhage in Women Undergoing D&E

  • Incidence similar between groups
    • Fetal death: 10% of women
    • Other indications: 7% of women
  • Associations with hemorrhage included
    • Fetal death: Adjusted odds ratio (OR) 2.9 (95% CI, 1.4 to 6.0; P=.006)
    • Prior vaginal delivery: aOR 1.7 (95% CI, 1.3 to 2.2: P<.001)
    • Prior cesarean delivery aOR 2.2 (95% CI, 1.7 to 3.0; P<.001)
    • Each additional week of gestation aOR 1.3 (95% CI, 1.3 to 1.4; P<.001)
  • Results remained the same using two different definitions for hemorrhage: 500 cc or as needing to apply interventions

DIC in Women Undergoing D&E

  • There was an increased incidence in the fetal death cohort (p<0.001)
  • In an unadjusted analysis, fetal death was associated with
    • 12.3 times higher odds of DIC (95% CI, 2.6 to 58.6)

Any Complications

  • The following were associated with any procedural complications (adjusted)
    • Fetal death: OR 3.0 (95% CI, 1.6 to 5.9, P=.001)
    • Prior vaginal delivery: OR 1.5 (95% CI 1.2 to 1.9; P<.001)
    • Prior cesarean delivery OR 1.8 (95% C,I 1.4 to 2.3; P<.001)
    • Each additional week of gestation OR 1.4 (95% CI, 1.3 to 1.4; P<.001)

CONCLUSION:

  • Fetal death was associated with 2.9 times higher odds of hemorrhage, 12.3 times higher for DIC and 3 times higher odds of any complication
  • Absolute risk for DIC still remains very low (2%)

Learn More – Primary Sources:

Disseminated Intravascular Coagulation and Hemorrhage After Dilation and Evacuation Abortion for Fetal Death

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Can the PlGF/sVEGFR-1 Ratio be Used to Predict Fetal Death?
Stillbirth Risks from 37 Weeks and Beyond
Diagnosing Preeclampsia – Key Definitions and ACOG Guidelines
Are Large-for-Gestational Age Pregnancies at an Increased Risk of Stillbirth?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site